Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 2Other hematologic neoplasm 2Sarcoma 1Other solid neoplasm 1Myeloid 1Lymphoid 1Gynecologic 1Gastrointestinal 1

Conditions

Sarcoma 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Colorectal Neoplasms 1Chondrosarcoma 1

Interventions

Gemcitabine 302Fluorouracil 296Oxaliplatin 269Bevacizumab 267Capecitabine 233Leucovorin 229pembrolizumab 215Irinotecan 185Cisplatin 142Cetuximab 142Nivolumab 131Paclitaxel 117130-nm albumin-bound paclitaxel 117Sorafenib 86Albumin-Bound Paclitaxel 75Docetaxel 65regorafenib 64atezolizumab 64IFL protocol 61Folfox protocol 61Trastuzumab 55Panitumumab 47durvalumab 46Ramucirumab 43Injections 43Sunitinib 41Drug Therapy 41Carboplatin 40trifluridine tipiracil drug combination 38lenvatinib 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × birinapant × Gastrointestinal × Clear all
NCT04553692 2025-03-28

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

IGM Biosciences, Inc.

Phase 1 Terminated
272 enrolled
GastrointestinalLymphoidOther hematologic neoplasmSarcoma

Chondrosarcoma, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡